Integrating multi-tissue transcriptomic signatures from Multiple Sclerosis studies with subgraph isomorphism algorithms will enable the identification of conserved molecular interaction motifs related to disease progression.
Adversarial Debate Score
62% survival rate under critique
Model Critiques
Supporting Research Papers
- Machine Learning for analysis of Multiple Sclerosis cross-tissue bulk and single-cell transcriptomics data
Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system whose molecular mechanisms remain incompletely understood. In this study, we developed an end-to-end machine learn...
- Transcriptomic Models for Immunotherapy Response Prediction Show Limited Cross-cohort Generalisability
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; yet substantial proportion of patients exhibit intrinsic or acquired resistance, making accurate pre-treatment response prediction ...
- Drug Synergy Prediction via Residual Graph Isomorphism Networks and Attention Mechanisms
In the treatment of complex diseases, treatment regimens using a single drug often yield limited efficacy and can lead to drug resistance. In contrast, combination drug therapies can significantly imp...
- Homology-based Morphometry of Brain Atrophy: Methods and Applications
Understanding the structure of the brain, and how it changes with time and disease, is a core goal of structural neuroimaging. Contemporary approaches to structural brain analysis are dominated by vox...
Formal Verification
Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.
This discovery has a Claude-generated validation package with a full experimental design.
Precise Hypothesis
Subgraph isomorphism algorithms applied to multi-tissue transcriptomic co-expression networks derived from ≥3 independent MS datasets (GSE193770, GSE108000, GSE138614) will identify conserved molecular interaction motifs — defined as recurring subgraph patterns of ≥4 nodes with edge-weight Pearson r ≥ 0.6 — that are (a) statistically enriched at chronic active rim (CA-RIM) lesion tissue relative to normal-appearing white matter (NAWR) and control tissue (FDR < 0.05, enrichment ratio ≥ 1.5×), (b) reproducible across ≥2 independent cohorts, and (c) contain ≥1 druggable node from the validated target hierarchy (DNMT1, ZNF740/BRD3, CTSS) with composite validation score ≥ 0.578. The null hypothesis is that subgraph isomorphism detects no motifs beyond those recoverable by standard pairwise DEG overlap (Jaccard similarity ≤ 0.15 improvement over baseline).
- PRIMARY DISPROOF: Subgraph isomorphism identifies zero motifs of ≥4 nodes with cross-cohort reproducibility (Jaccard ≥ 0.3 between GSE193770 and GSE138614 motif sets) after FDR correction — i.e., all candidate motifs are cohort-specific artifacts.
- PERFORMANCE DISPROOF: Motif-based target ranking produces AUC ≤ 0.55 for predicting the known validated targets (DNMT1, ZNF740, CTSS) versus random gene selection, indicating no predictive advantage over baseline DEG analysis.
- NOVELTY DISPROOF: All conserved motifs identified are fully recoverable by pairwise DEG overlap (Jaccard similarity improvement < 0.15 over standard intersection of top-500 DEGs per dataset), demonstrating no added value from subgraph isomorphism.
- BIOLOGICAL DISPROOF: Conserved motifs show no significant GO/pathway enrichment (FDR > 0.1) in MS-relevant processes (neuroinflammation, T-cell activation, epigenetic regulation, MHC antigen presentation) — motifs are statistically present but biologically uninformative.
- REPLICATION DISPROOF: Motifs identified in GSE193770 fail to replicate in GSE138614 at FDR < 0.1 (even relaxed threshold), with overlap < 10% of motif nodes, indicating dataset-specific overfitting.
- CELL-TYPE DISPROOF: Motifs containing DNMT1 or ZNF740 nodes are not CD8+ T-cell-restricted when tested in single-cell data (expressed in ≥3 additional cell types at comparable levels, log2FC difference < 0.5), invalidating the mechanistic specificity claim.
- DRUG TARGET DISPROOF: No motif hub node maps to a compound with pChEMBL ≥ 6.0 in ChEMBL, rendering the computational discovery therapeutically inactionable.
Experimental Protocol
MINIMUM VIABLE TEST (MVT) — 3-phase design targeting 45-day completion:
PHASE A — Network Construction & Motif Discovery (Days 1–20): Construct tissue-stratified co-expression networks from three GEO datasets. For bulk datasets (GSE108000, GSE138614): VST-normalize counts, compute FDR-corrected partial correlations (PCIT or GeneNet R package), threshold at r ≥ 0.6, build adjacency matrices. For single-cell dataset (GSE193770): use scVI latent space correlations from the pre-built atlas (gs://aegismind-tpu-results/ms_phase2/results/) to construct cell-type-stratified networks, focusing on CD8+ T-cell cluster (Leiden cluster identity to be confirmed from atlas). Apply VF2++ subgraph isomorphism algorithm (NetworkX implementation, GPU-accelerated via cuGraph) to enumerate recurring subgraphs of size k = 4, 5, 6, 7, 8 nodes. Use gSpan or GRAMI for frequent subgraph mining with minimum support threshold = 2/3 datasets.
PHASE B — Statistical Validation & Enrichment (Days 21–35): Compute motif enrichment scores versus 10,000 permuted networks (node-label permutation preserving degree distribution). Apply Bonferroni correction. Map motif hub nodes to: (i) the 50-gene MS seed set for proximity scoring, (ii) ChEMBL druggability database, (iii) the validated target hierarchy. Perform GO/KEGG enrichment on motif node sets (clusterProfiler). Compute Jaccard similarity of motif node sets between cohort pairs.
PHASE C — Biological Validation (Days 36–45): For top 3 conserved motifs: validate hub node expression in CD8+ T cells using FACS-sorted PBMC from 10 smoldering MS patients versus 10 healthy controls (if samples available) OR re-analyze existing sorted data from GSE193770. Test whether motif hub nodes predict CA-RIM pathology score using logistic regression (AUC as primary metric). Generate network visualization and report.
- GSE193770 — Primary single-cell RNA-seq dataset; 36,966 cells, MS lesion tissue; available GEO; CD8+ T-cell clusters critical for DNMT1/ZNF740 validation. Download size: ~8 GB.
- GSE108000 — Bulk RNA-seq, MS white matter lesions vs. controls; used in Phase 1 DEG pipeline (1,065 DEGs); available GEO. Download size: ~2 GB.
- GSE138614 — Replication bulk RNA-seq cohort; validated CTSS (log2FC +1.024, FDR 0.111) and FGF2/SLCO2B1; available GEO. Download size: ~1.5 GB.
- Pre-built scVI atlas — gs://aegismind-tpu-results/ms_phase2/results/; 30 Leiden clusters; saves ~2 weeks of retraining. Access: Google Cloud Storage (requester-pays or collaborator access required).
- CELLxGENE Census — Cross-modal integration reference; human CNS cells; access via cellxgene-census Python API (free). Estimated relevant subset: ~50,000 CNS cells.
- GTEx v10 — Expression reference for CTSS blood TPM validation (229.8 TPM confirmed); available via GTEx portal. Relevant tissue: whole blood, brain subregions.
- ChEMBL v33 — Druggability mapping for motif hub nodes; >100 CTSS inhibitors (best pChEMBL 10.0); REST API or local PostgreSQL dump (~25 GB).
- STRING v12 — PPI network for proximity scoring against 50-gene MS seed set; pre-computed distance matrices available. Download: ~15 GB full network.
- MS seed gene set (50 genes) — From Phase 4 of published pipeline; available at github.com/tradingjohn/ms-transcriptomics-carrim.
- OPTIONAL — PBMC samples from 10 smoldering MS + 10 HC donors for FACS-sorted CD8+ T-cell RT-qPCR validation of top motif hubs (wet-lab component; IRB-dependent).
- MOTIF DISCOVERY: ≥5 conserved motifs (k ≥ 4 nodes) identified with Bonferroni-corrected p < 0.05 across ≥2 of 3 datasets.
- CROSS-COHORT REPRODUCIBILITY: Jaccard similarity of motif node sets between GSE193770 and GSE138614 ≥ 0.30.
- NOVELTY OVER BASELINE: ΔJaccard (motif vs. DEG overlap) ≥ 0.15; motif method recovers ≥20% additional disease-relevant genes not in standard DEG intersection.
- TARGET RECOVERY: ≥2 of 3 primary targets (DNMT1, ZNF740, CTSS) appear as hub nodes (top-10% centrality) in conserved motifs.
- BIOLOGICAL RELEVANCE: ≥3 conserved motifs show GO/KEGG enrichment (FDR < 0.05) in neuroinflammation, T-cell activation, or epigenetic regulation pathways.
- DRUGGABILITY: ≥1 conserved motif hub node maps to ChEMBL compound with pChEMBL ≥ 7.0 (beyond the already-known targets).
- PREDICTIVE PERFORMANCE: Logistic regression AUC ≥ 0.70 (95% CI lower bound ≥ 0.60) for CA-RIM pathology prediction using motif hub node expression.
- SMOLDERING SPECIFICITY: Conserved motifs show ≥1.5× enrichment ratio in smoldering MS vs. RRMS samples (FDR < 0.05) in at least one dataset.
- COMPUTATIONAL EFFICIENCY: Full motif enumeration for k ≤ 8 completes within 72 GPU-hours, demonstrating practical scalability.
- REPLICATION OF PUBLISHED TARGETS: CTSS log2FC in GSE138614 replicates within ±15% of published value (+1.024); FGF2 FDR < 0.05 in replication analysis.
- HARD FAILURE — ZERO CONSERVED MOTIFS: No motifs of k ≥ 4 survive Bonferroni correction across ≥2 datasets after 10,000 permutations → hypothesis rejected.
- HARD FAILURE — NO NOVELTY: ΔJaccard < 0.05 (motif method performs at or below DEG overlap baseline) → subgraph isomorphism adds no value over existing methods.
- HARD FAILURE — TARGET MISS: Neither DNMT1 nor CTSS (the two highest-confidence targets) appear in top-20% centrality of any conserved motif → computational framework fails to recover validated biology.
- HARD FAILURE — REPLICATION FAILURE: Jaccard similarity of motif node sets between any two cohort pairs < 0.10 → motifs are dataset-specific artifacts, not conserved signatures.
- SOFT FAILURE — POOR PREDICTION: AUC < 0.60 for CA-RIM prediction → motifs are statistically present but not clinically informative.
- SOFT FAILURE — NO BIOLOGICAL ENRICHMENT: Zero conserved motifs show GO/KEGG FDR < 0.10 → motifs lack interpretable biological meaning.
- SOFT FAILURE — COMPUTATIONAL INTRACTABILITY: k=8 motif enumeration exceeds 200 GPU-hours without convergence → algorithm does not scale to biologically meaningful motif sizes.
- SOFT FAILURE — CALIBRATION MISS: DEG replication in Step 3 shows >25% deviation from published DNMT1/CTSS/ZNF740 values → data processing error invalidates downstream analysis.
- SOFT FAILURE — CELL-TYPE CONTAMINATION: DNMT1 or ZNF740 motifs are not CD8+ T-cell-restricted in single-cell analysis (expressed in ≥3 other clusters at comparable levels) → mechanistic specificity claim unsupported.
100
GPU hours
30d
Time to result
$1,000
Min cost
$10,000
Full cost
ROI Projection
- SMOLDERING MS THERAPEUTICS: No FDA-approved therapy specifically targets the CA-RIM compartment. Validated motifs containing DNMT1 or CTSS as hubs provide mechanistic rationale for first-in-class IND filings. DNMT1 inhibitors (decitabine, Inqovi) are already approved in hematology at sub-myelosuppressive doses shown to reprogram autoimmune T cells — motif validation could support MS label expansion (estimated $500M–$1.5B peak sales for a repositioned DNMT1 inhibitor in progressive MS).
- CTSS INHIBITOR PROGRAM: RO5459072 has Phase 2 safety data (NCT02701985, Sjögren's). Motif validation elevating CTSS to a conserved hub node in smoldering MS provides the mechanistic package needed for a Phase 2 MS trial. Estimated development cost to Phase 2 readout: $15–25M; licensing value post-Phase 2: $150–400M.
- BET INHIBITOR CNS PROGRAM: ZNF740/BRD3 motif validation creates commercial rationale for CNS-penetrant BET inhibitor development (currently unmet need). Partnership value with BET inhibitor companies (Constellation Pharmaceuticals/MorphoSys, Incyte): estimated $20–80M deal value.
- COMPUTATIONAL PLATFORM LICENSING: The subgraph isomorphism pipeline (open-source base at github.com/tradingjohn/ms-transcriptomics-carrim) could be commercialized as a SaaS tool for pharma target identification. Comparable platforms (e.g., BioSymetrics, Recursion): $2–10M ARR at scale.
- DIAGNOSTIC BIOMARKER PANEL: Motif hub nodes with blood expression (CTSS, FGF2) could be developed as a companion diagnostic for smoldering MS patient stratification. Licensing to diagnostics companies (Roche Diagnostics, Biogen): $5–30M upfront + royalties.
- ACADEMIC SPINOUT POTENTIAL: Combined computational + biomarker + therapeutic target package supports a spinout company with Series A valuation of $15–50M based on comparable neuro-AI companies (2024–2026 benchmarks).
TIME_TO_RESULT_DAYS: 45
🔓 If proven, this unlocks
Proving this hypothesis is a prerequisite for the following downstream discoveries and applications:
- 1ZNF740-BRD3-motif-pharmacology-EVP
- 2DNMT1-epigenetic-reprogramming-CD8-EVP
- 3CTSS-liquid-biopsy-biomarker-EVP
- 4multi-tissue-motif-drug-combination-EVP
- 5smoldering-MS-progression-biomarker-panel-EVP
- 6subgraph-isomorphism-autoimmune-generalization-EVP
- 7FGF2-SLCO2B1-motif-context-EVP
Prerequisites
These must be validated before this hypothesis can be confirmed:
- GSE193770-scVI-atlas-validation
- MS-seed-gene-set-v1-50genes
- CA-RIM-DEG-pipeline-GSE108000
- CTSS-replication-GSE138614
- ChEMBL-druggability-mapping-v33
Implementation Sketch
# ============================================================ # EVP IMPLEMENTATION SKETCH: Subgraph Isomorphism MS Motif Discovery # Target runtime: 45 days | GPU: 85h | CPU: 320h | RAM: 512GB # ============================================================ # --- PHASE A: DATA LOADING & NETWORK CONSTRUCTION --- import scanpy as sc import scvi import networkx as nx import numpy as np import pandas as pd from scipy.stats import pearsonr, spearmanr from gspan_mining import gSpan # pip install gspan-mining import cugraph # GPU-accelerated graph ops import anndata # Step 1: Load pre-built scVI atlas (saves ~2 weeks retraining) atlas = sc.read_h5ad("gs://aegismind-tpu-results/ms_phase2/results/atlas.h5ad") # Confirm CD8+ T-cell cluster cd8_mask = atlas.obs['leiden'].isin(identify_cd8_clusters(atlas)) cd8_adata = atlas[cd8_mask].copy() # Expected: ~4,000–8,000 CD8+ T cells from 36,966 total # Step 2: Load bulk datasets bulk_datasets = { 'GSE108000': load_geo_bulk('GSE108000', normalize='VST'), 'GSE138614': load_geo_bulk('GSE138614', normalize='VST') } # Step 3: Define gene universe (DEG union + MS seed set) deg_genes = load_deg_list('carrim_degs_1065.txt') # from GitHub repo ms_seed = load_seed_set('ms_seed_50genes.txt') gene_universe = list(set(deg_genes) | set(ms_seed)) # ~1,100 genes # Step 4: Calibration checkpoint — verify published DEG values def calibrate_degs(adata, expected_values): """Verify DNMT1, CTSS, ZNF740 log2FC within ±10% of published""" results = run_deseq2(adata, contrast=['condition', 'CA-RIM', 'NAWM']) for gene, expected_fc in expected_values.items(): observed_fc = results.loc[gene, 'log2FoldChange'] assert abs(observed_fc - expected_fc) / abs(expected_fc) < 0.10, \ f"CALIBRATION FAIL: {gene} FC={observed_fc:.3f}, expected={expected_fc:.3f}" return results expected = {'DNMT1': 1.59, 'CTSS': 1.16, 'ZNF740': 1.15} calibrate_degs(bulk_datasets['GSE108000'], expected) # ABORT if fails # --- NETWORK CONSTRUCTION --- def build_coexpression_network(expr_matrix, genes, method='partial_corr', threshold=0.6): """ Build co-expression network with FDR-corrected partial correlations. Returns: NetworkX Graph with edge weights """ expr_subset = expr_matrix[genes].dropna(axis=1) if method == 'partial_corr': # Use R GeneNet via rpy2 for FDR-corrected partial correlations import rpy2.robjects as ro pcor_matrix = ro.r(f''' library(GeneNet) data <- as.matrix(read.csv("expr_temp.csv")) pcor <- ggm.estimate.pcor(data) test.results <- network.test